Pfizer (PFE) Stock

$25.53 -0.11 (-0.43%)
Market Cap: $144.68B | NYSE

Pfizer Chart


Company Profile

Price: $25.53

Market Cap: $144.68B

Exchange: NYSE

CEO: Dr. Albert Bourla D.V.M., Ph.D.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 88.00K

Headquarters: New York, NY

Website: Pfizer

Business Summary

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer News

The Big 3: AMSC, PFE, GOLD

Alan Knuckman turns to stocks he believes aren't as renowned as their peers. He explains why he's watching American Superconductor (ASMC), Pfizer (PFE), and Barrick Gold (GOLD) for today's Big 3.

News image

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The TALAPRO-2 results will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco and featured in the ASCO GU official Press Program. The TALAPRO-2 study evaluated two sets of patients, unselected (cohort 1) and selected for HRR gene-mutations (cohort 2). Overall survival was a prespecified, alpha-protected key secondary endpoint. After more than four years of median follow-up (52.5 months), the median OS in cohort 1 was 45.8 months with TALZENNA in combination with XTANDI, and 37.0 months with XTANDI and placebo (Hazard Ratio [HR] of 0.80; 95% Confidence Interval [CI], 0.66-0.96; p=0.015), representing a 20% reduction in the risk of death. This represents a nearly 9-month gain in median OS versus standard of care XTANDI. Data from cohort 1 will be presented today at ASCO GU in an oral presentation (Abstract LBA18) by Dr. Neeraj Agarwal, global lead investigator for TALAPRO-2. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); In Cohort 2, a statistically significant and clinically meaningful improvement in OS was observed in patients with HRR-mutated mCRPC. At a median follow-up of 44.2 months, the median OS was 45.1 months with TALZENNA in combination with XTANDI, and 31.1 months with XTANDI and placebo (HR of 0.62; 95% CI, 0.48-0.81; p=0.0005), a 38% reduction in the risk of death. This result represents a 14-month gain in median OS versus standard of care XTANDI in a patient population with a historically poor prognosis. The OS improvement in the HRR-mutated population was observed in patients in both BRCA and non-BRCA gene alterations. Dr. Karim Fizazi, Institut Gustave Roussy, University of Paris-Saclay will share data from Cohort 2 at ASCO GU today (Abstract LBA141). “Since its approval, TALZENNA in combination with XTANDI has redefined the standard of care for those living with homologous recombination repair gene-mutated mCRPC. These latest data from TALAPRO-2 are extremely compelling, demonstrating that the combination significantly extended overall survival, in patients selected and unselected for HRR gene alterations, potentially shifting the treatment paradigm for all men living with mCRPC,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “Although definitive conclusions cannot be drawn across studies, these results appear to represent the longest median overall survival reported in a randomized, controlled Phase 3 trial in mCRPC. We look forward to continuing to work with global authorities to potentially update the TALZENNA label with these results.” “TALAPRO-2 is the first study demonstrating a significant and clinically meaningful survival benefit using a combination of PARP and androgen receptor inhibitors in mCRPC,” said Neeraj Agarwal, M.D., FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and global lead investigator for TALAPRO-2. “Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in combination with XTANDI to be a practice-changing treatment to help improve patient survival in mCRPC.” At the time of the final analysis, updated radiographic progression free survival (rPFS) and other secondary efficacy endpoints demonstrated maintained clinical benefit in both cohorts and were consistent with the primary analyses previously reported and published in The Lancet and Nature Medicine. In addition to the FDA, these data have been shared with the European Medicines Agency (EMA) and other global health authorities to support potential updates of the approved labels for TALZENNA. The safety profile of TALZENNA plus XTANDI was generally consistent with the known safety profile of each medicine. The most common all-cause adverse events in the TALZENNA group (≥30% of patients) were anemia, neutropenia, and fatigue, and the most common (≥10% of patients) grade 3–4 adverse events were anemia (49%) and neutropenia (19.3%). Adverse events were generally manageable with dose modification and supportive care. About Metastatic Castration-Resistant Prostate Cancer Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death among men worldwide, with an estimated 1.4 million new cases diagnosed in 2022.1 In the U.S., it is the most common cancer in men.2 mCRPC is a cancer that has spread beyond the prostate gland and has progressed despite medical or surgical treatment to lower testosterone. Approximately 10–20% of prostate cancer patients develop mCRPC within 5−7 years of diagnosis.3 Between 1.2–2.1% of all prostate cancer cases globally are mCRPC.4 About TALAPRO-2 The Phase 3 TALAPRO-2 trial is a multicenter, randomized, double-blind, placebo-controlled study that enrolled 1,035 unique patients with mCRPC who had not received new life-prolonging systemic treatments after documentation of mCRPC at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The study included two patient cohorts: unselected (n=805, of whom 169 had HRR mutations and 636 did not) and those with HRR gene mutations (n=399, including 169 patients from Cohort 1 and 230 subsequently enrolled to comprise Cohort 2). Patients with castrate testosterone levels were randomized to receive TALZENNA 0.5 mg/day plus XTANDI 160mg/day, or placebo plus XTANDI 160mg/day. The primary endpoint of the trial was rPFS, defined as the time from the date of randomization to first objective evidence of radiographic progression by blinded independent central review (BICR), or death, whichever occurred first, in both Cohort 1 (unselected) and Cohort 2 (those with HRRm). Secondary endpoints included OS, objective response rate (ORR), duration of response (DoR), prostate-specific antigen (PSA) response, time to cytotoxic chemotherapy and PFS2. For more information on the TALAPRO-2 trial (NCT03395197), go to www.clinicaltrials.gov. About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. TALZENNA was initially approved in the U.S., EU, and multiple other regions as a single agent for the treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2-negative locally advanced or metastatic breast cancer. TALZENNA in combination with XTANDI was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC in June 2023. The combination was also approved by the European Commission in January 2024 for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. TALZENNA is the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations. TALZENNA in combination with XTANDI is now approved in more than 40 countries globally for patients with mCRPC, indications vary by country. TALZENNA® (talazoparib) Indication in the U.S. TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: HRR gene-mutated mCRPC: In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Breast Cancer: As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. TALZENNA® (talazoparib) Important Safety Information WARNINGS and PRECAUTIONS Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA. Overall, MDS/AML has been reported in 0.4% (3 out of 788) of solid tumor patients treated with TALZENNA as a single agent in clinical studies. In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide. The durations of TALZENNA treatment in these five patients prior to developing MDS/AML were 0.3, 1, 2, 3, and 5 years, respectively. Most of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA. Myelosuppression consisting of anemia, neutropenia, and/or thrombocytopenia have been reported in patients treated with TALZENNA. In TALAPRO-2, Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 45%, 18%, and 8% of patients receiving TALZENNA and enzalutamide. Overall, 39% of patients (199/511) required a red blood cell transfusion, including 22% (111/511) who required multiple transfusions. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 7%, 3%, and 0.4% of patients. Withhold TALZENNA until patients have adequately recovered from hematological toxicity caused by previous therapy. Monitor blood counts monthly during treatment with TALZENNA. If hematological toxicities do not resolve within 28 days, discontinue TALZENNA and refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. Embryo-Fetal Toxicity TALZENNA can cause fetal harm when administered to pregnant women. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment with TALZENNA and for 4 months after receiving the last dose. ADVERSE REACTIONS In TALAPRO-2, serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each). The most common adverse reactions (≥ 10%, all Grades), including laboratory abnormalities, for patients in the TALAPRO-2 study who received TALZENNA in combination with enzalutamide vs patients receiving placebo with enzalutamide were hemoglobin decreased (79% vs 34%), neutrophils decreased (60% vs 18%), lymphocytes decreased (58% vs 36%), fatigue (49% vs 40%), platelets decreased (45% vs 8%), calcium decreased (25% vs 11%), nausea (21% vs 17%), decreased appetite (20% vs 14%), sodium decreased (22% vs 20%), phosphate decreased (17% vs 13%), fractures (14% vs 10%), magnesium decreased (14% vs 12%), dizziness (13% vs 9%), bilirubin increased (11% vs 7%), potassium decreased (11% vs 7%), and dysgeusia (10% vs 4.5%). Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%). Based on animal studies, TALZENNA may impair fertility in males of reproductive potential. DRUG INTERACTIONS Coadministration with P-gp inhibitors The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken in combination with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor. Coadministration with BCRP inhibitors Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a BCRP inhibitor. Coadministration of TALZENNA with BCRP inhibitors may increase talazoparib exposure, which may increase the risk of adverse reactions. USE IN SPECIFIC POPULATIONS Renal Impairment The recommended dosage of TALZENNA for patients with moderate renal impairment (CLcr 30 - 59 mL/min) is 0.35 mg taken orally once daily in combination with enzalutamide. The recommended dosage of TALZENNA for patients with severe renal impairment (CLcr 15 - 29 mL/min) is 0.25 mg taken orally once daily in combination with enzalutamide. No dose adjustment is required for patients with mild renal impairment. TALZENNA has not been studied in patients requiring hemodialysis. Please see full U.S. Prescribing Information and Patient Information for TALZENNA ® (talazoparib) at www.TALZENNA.com. About XTANDI ® (enzalutamide) and Important Safety Information XTANDI® (enzalutamide) is an androgen receptor signaling inhibitor. XTANDI is a standard of care and has received regulatory approvals in one or more countries around the world for use in men with metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic hormone-sensitive prostate cancer or mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). XTANDI is currently approved for one or more of these indications in more than 90 countries, including in the U.S., EU, and Japan. Over one million patients have been treated with XTANDI globally.6 What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose. Males must use a condom during sex with a pregnant female. Are breastfeeding or plan to breastfeed. It is not known if XTANDI passes into your breast milk. Take other medicines. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works. These include prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not start or stop any medicine without talking to your doctor. How should I take XTANDI?Take XTANDI exactly as your doctor tells you. Take your prescribed dose once a day, at the same time each day. XTANDI can be taken with or without food. Swallow XTANDI capsules or tablets whole with enough water to make sure that you can swallow all of the medicine successfully. Do not chew, dissolve, or open the capsules. Do not cut, crush or chew the tablets. Your doctor may change your dose if needed. Your doctor may also change your pill size or stop treatment if you have swallowing problems. Do not change or stop taking your prescribed dose of XTANDI without talking with your doctor first. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment while taking XTANDI unless you have had surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of XTANDI: Take your prescribed dose as soon as you remember that day. If you miss your daily dose, take your prescribed dose at your regular time the next day. Do not take more than your prescribed dose of XTANDI each day. If you take too much XTANDI: Call your doctor or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI. What are the possible side effects of XTANDI? XTANDI may cause serious side effects including:Seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Posterior Reversible Encephalopathy Syndrome (PRES). If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your doctor right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems. Your doctor will do a test to check for PRES. Allergic Reactions. Allergic reactions have happened in people who take XTANDI. Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat. Heart Disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI. Your doctor will monitor you for signs and symptoms of heart problems during your treatment. Call your doctor or go to the emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI. Falls and Bone Fractures. XTANDI treatment may increase your risk for falls and bone fractures. Falls were not caused by loss of consciousness or seizures. Your doctor will monitor your risks for falls and bone fractures during treatment with XTANDI. Swallowing problems or choking. Severe swallowing problems or choking, including life-threatening problems or death can happen in people during treatment with XTANDI, because of the size of the XTANDI capsules and tablets. Swallow each XTANDI capsule or tablet whole with enough water to make sure that you can swallow all of the medicine successfully. Your doctor will stop treatment with XTANDI if you have serious side effects. The most common side effects of XTANDI include: Muscle and joint pain Feeling more tired than usual Hot flashes Constipation Decreased appetite Diarrhea High blood pressure Bleeding problems Falls Bone fractures Headache XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility. These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. About the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE: PFE), and Astellas (TSE: 4503) entered into a global agreement to jointly develop and commercialize XTANDI ® (enzalutamide). The companies jointly commercialize XTANDI in the United States, and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States. Disclosure Notice The information contained in this release is as of February 13, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology, TALZENNA and XTANDI, including their potential benefits, the TALAPRO-2 results, and potential updates of the approved labels for TALZENNA that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of TALZENNA in combination with XTANDI; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications for TALZENNA, XTANDI or a combination may be filed in any jurisdictions for any potential indications; whether and when any applications for TALZENNA, XTANDI or a combination that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether TALZENNA, XTANDI or a combination will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of TALZENNA, XTANDI or a combination; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. References Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians . 2024;74(3):229-263. Published 2024 April 4. doi: 10.3322/caac.21834 American Cancer Society. Key Statistics for Prostate Cancer. Accessed August 2024. *other than non-melanoma skin cancer Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. PMID: 21995694. Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2021 Apr;205(4):977-986. doi: 10.1097/JU.0000000000001570. Epub 2020 Dec 17. PMID: 33332152. https://www.auajournals.org/doi/10.1097/JU.0000000000001570 National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer, Bethesda, MD, USA (2022); USA. Accessed December 2024. https://seer.cancer.gov/statfacts/html/prost.html. Data on file. Northbrook, IL: Astellas Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20250213091824/en/

News image

Are Investors Being Too Paranoid About Pfizer Stock?

Investing in a top healthcare company whose share price has been tanking in recent years could present a huge opportunity for investors, especially when that company has been bolstering its growth prospects via acquisitions and expansion of its pipeline. And if that stock trades at a cheap valuation and pays a high dividend, it would seem like a no-brainer buy today.

News image

3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now

With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers no shortage of ways for investors to grow their wealth. But among this vast sea of pathways to become richer is one of the most-successful strategies: buying and holding high-quality dividend stocks.

News image

U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grad.

News image

Pfizer: 3 Key Risks That Warrant A Sell

Pfizer's business is facing material revenue shrink issues due to many patent expirations over the next 3 years. Quarterly revenue run rate analysis suggests management may be underestimating the impact. PFE continues to have recurring 'unusual charges.' Accounting for this, its EBIT margins are in barely profitable territory. The Company is trading at a 32% 1-yr fwd PE discount to peers, but I think this is deserved given its revenue and profitability challenges.

News image

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

News image

Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothel.

News image

A Historic Opportunity To Win Big With Dividend Stocks

The current market offers a historic opportunity for dividend stocks. We detail why this is a historic opportunity for dividend investors. We also discuss some of the names that we are buying to take advantage of this opportunity.

News image

Should Pfizer Stock Be in Your Portfolio Post a Robust Q4 Performance?

Investors may stay invested in PFE stock to see how its new growth drivers perform.

News image

Pfizer: Challenges Loom Amid Overvaluation

I have downgraded Pfizer Inc. stock to Strong Sell due to stagnant revenue, substantial patent cliffs, regulatory, legal, and reputational headwinds, and overvaluation concerns. Despite a 24.7% YoY revenue growth in FQ4, Pfizer's financial flexibility remains weak with significant net debt and no new products to offset patent losses. Valuation analysis indicates PFE stock is overvalued with a fair share price below $25, and consensus estimates forecast a below 2% dividend growth rate for the next two fiscal years.

News image

Better High-Yield Dividend Stock: Pfizer vs. Merck

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.

News image

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.

News image

Fighting Cancer Becomes Top Priority for Pfizer

Pfizer chairman and CEO Albert Bourla sees cancer as Pfizer's next big chance to save the world. The complexity of cancers makes treatments expensive to develop and challenging to customize, but the approach of making life more livable with cancer is changing the face of the disease.

News image

Is Now a Good Time to Buy the Dip on Pfizer?

The past three years have been difficult for Pfizer (PFE -0.35%). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt.

News image

3 Dividend Stocks to Double Up on Right Now

What's better than a good thing? More of a good thing.

News image

Income Strategy: I'm Stashing Cash Into These Wonderful Dividends

Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I highlight two such names that offer robust payouts which are well-covered by earnings. Both carry moat-worthy business models and have strong pipelines that support potential for robust total returns.

News image

3 Top Dividend Stocks to Buy in February

Dividend stocks are increasingly appealing for investors in 2025 due to their potential for steady income and resilience in volatile markets.

News image

Should You Pick PFE Stock At $25?

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectively.

News image

MoneyShow's Best Investment Ideas For 2025: Part 9

MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 9 includes Ituran Location and Control, Lara Exploration, Imperial Oil, Avino Silver & Gold Mines, BBB Foods and Pfizer, among others.

News image

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

News image

Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript

Pfizer, Inc. (NYSE:PFE ) Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ET Company Participants Francesca DeMartino - Senior Vice President, Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer and President of Research & Development Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Geoff Meacham - Citibank Chris Schott - JPMorgan Vamil Divan - Guggenheim Securities Courtney Breen - Bernstein Evan Seigerman - BMO Capital Markets Kripa Devarakonda - Truist Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Trung Huynh - UBS Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Operator Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded.

News image

Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales

PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.

News image

Nasdaq Surges Over 1%; Pfizer Earnings Top Estimates

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

News image

Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job

Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.

News image

Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary

Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.

News image

Pfizer's fourth quarter sales and earnings top expectations

Pfizer Inc (NYSE:PFE, ETR:PFE) posted stronger-than-expected financial results for the fourth quarter and reaffirmed its 2025 revenue guidance. The company continues to expect between $61 billion and $64 billion in revenue this year, with sales from Covid products expected to be stable year-over-year.

News image

Compared to Estimates, Pfizer (PFE) Q4 Earnings: A Look at Key Metrics

The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News image

PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.

News image

2 Blue-Chip Drug Stocks in Focus Today After Earnings

Stocks are struggling for direction  today, and one sector that represents this choppiness is blue-chip drugmakers.

News image

Pfizer Earnings

This section highlights Pfizer's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: May 07, 2025
Time: Before Market
Est. EPS: $0.63
Status: Unconfirmed

Last Earnings Results

Date: February 04, 2025
EPS: $0.63
Est. EPS: $0.47
Revenue: $17.76B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-02-04 $0.47 $0.63
Read Transcript Q3 2024 2024-10-29 $0.61 $1.06
Read Transcript Q2 2024 2024-07-30 $0.46 $0.60
Read Transcript Q1 2024 2024-05-01 $0.52 $0.82
Read Transcript Q4 2023 2024-01-30 $-0.19 $0.10
Read Transcript Q3 2023 2023-10-31 $-0.32 $-0.17
Read Transcript Q2 2023 2023-08-01 $0.56 $0.67
Read Transcript Q1 2023 2023-05-02 $0.98 $1.23

Financial Statements

Access annual & quarterly financial statements for Pfizer, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $63.63B $58.50B $100.33B $81.29B $41.91B
Cost of Revenue $17.85B $29.69B $34.34B $30.82B $8.69B
Gross Profit $45.78B $28.81B $65.99B $50.47B $33.22B
Gross Profit Ratio 71.94% 49.25% 65.77% 62.08% 79.26%
Research and Development Expenses $10.93B $10.68B $11.43B $13.83B $9.40B
General and Administrative Expenses $- $11.07B $10.88B $10.70B $9.81B
Selling and Marketing Expenses $- $3.70B $2.80B $2.00B $1.80B
Selling General and Administrative Expenses $14.73B $14.77B $13.68B $12.70B $11.62B
Other Expenses $5.18B $- $3.61B $3.70B $3.44B
Operating Expenses $30.84B $25.45B $28.71B $30.23B $24.46B
Cost and Expenses $42.12B $55.14B $63.06B $61.05B $33.15B
Interest Income $545.00M $1.62B $251.00M $36.00M $73.00M
Interest Expense $3.09B $2.21B $1.24B $1.29B $1.45B
Depreciation and Amortization $-3.82B $6.29B $5.06B $5.19B $4.68B
EBITDA $11.11B $9.56B $41.03B $30.79B $13.17B
EBITDA Ratio 17.47% 16.34% 43.50% 35.10% 33.56%
Operating Income $14.94B $3.36B $40.03B $24.83B $10.63B
Operating Income Ratio 23.48% 5.74% 39.90% 30.55% 25.37%
Total Other Income Expenses Net $-6.92B $-2.30B $-2.54B $-2.67B $-3.59B
Income Before Tax $8.02B $1.06B $34.73B $24.31B $7.50B
Income Before Tax Ratio 12.61% 1.81% 34.61% 29.91% 17.89%
Income Tax Expense $28.00M $-1.11B $3.33B $1.85B $477.00M
Net Income $8.03B $2.12B $31.37B $21.98B $7.02B
Net Income Ratio 12.62% 3.62% 31.27% 27.04% 16.75%
EPS $1.42 $0.38 $5.59 $3.95 $1.26
EPS Diluted $1.41 $0.37 $5.47 $3.88 $1.25
Weighted Average Shares Outstanding 5.66B 5.64B 5.61B 5.60B 5.55B
Weighted Average Shares Outstanding Diluted 5.70B 5.71B 5.73B 5.71B 5.63B
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown December 31, 2024 September 29, 2024 June 30, 2024 March 31, 2024 December 31, 2023 October 01, 2023 July 02, 2023 April 02, 2023 December 31, 2022 October 02, 2022 July 03, 2022 April 03, 2022 December 31, 2021 October 03, 2021 July 04, 2021 April 04, 2021 December 31, 2020 September 27, 2020 June 28, 2020 March 29, 2020
Revenue $17.76B $17.70B $13.28B $14.88B $14.25B $13.23B $12.73B $18.28B $24.29B $22.64B $27.74B $25.66B $23.84B $24.09B $18.98B $14.58B $11.68B $12.13B $11.80B $12.03B
Cost of Revenue $5.91B $6.58B $5.04B $4.38B $8.59B $10.60B $4.59B $6.05B $9.65B $6.06B $9.07B $9.98B $9.74B $9.97B $7.05B $4.21B $2.92B $2.53B $2.28B $2.38B
Gross Profit $11.85B $11.13B $8.24B $10.50B $5.66B $2.63B $8.14B $12.23B $14.64B $16.57B $18.68B $15.68B $14.10B $14.12B $11.93B $10.37B $8.77B $9.60B $9.52B $9.65B
Gross Profit Ratio 66.73% 62.86% 62.06% 70.56% 39.70% 19.87% 63.92% 66.92% 60.28% 73.22% 67.32% 61.09% 59.16% 58.61% 62.86% 71.12% 75.02% 79.15% 80.67% 80.23%
Research and Development Expenses $3.12B $2.60B $2.68B $2.48B $2.77B $2.68B $2.63B $2.49B $3.62B $2.70B $2.81B $2.30B $5.92B $3.45B $2.46B $2.01B $3.35B $2.36B $2.13B $1.72B
General and Administrative Expenses $- $- $- $- $777.00M $- $- $- $1.84B $- $- $- $2.10B $- $- $- $350.00M $- $-221.00M $-129.00M
Selling and Marketing Expenses $- $- $- $- $3.70B $- $- $- $2.80B $- $- $- $2.00B $- $- $- $-5.90B $- $3.03B $2.87B
Selling General and Administrative Expenses $4.27B $3.24B $3.69B $3.46B $4.48B $3.21B $3.43B $3.36B $4.64B $3.39B $2.91B $2.59B $4.10B $2.90B $2.93B $2.78B $3.76B $3.02B $3.03B $2.87B
Other Expenses $1.27B $- $230.00M $361.00M $1.03B $574.00M $385.00M $680.00M $1.13B $822.00M $-104.00M $835.00M $1.31B $1.48B $650.00M $658.00M $641.00M $122.00M $274.00M $318.00M
Operating Expenses $7.86B $5.84B $6.36B $5.94B $7.25B $5.89B $6.06B $5.85B $9.39B $6.91B $5.73B $5.73B $10.98B $7.33B $6.32B $5.67B $7.97B $6.27B $6.07B $5.48B
Cost and Expenses $13.61B $12.42B $11.40B $10.32B $15.84B $16.50B $10.66B $11.90B $19.04B $12.97B $14.79B $15.71B $20.71B $17.31B $13.37B $9.88B $10.89B $8.80B $8.35B $7.86B
Interest Income $170.00M $116.00M $130.00M $129.00M $609.00M $523.00M $316.00M $177.00M $137.00M $70.00M $30.00M $14.00M $14.00M $10.00M $13.00M $- $4.00M $17.00M $19.00M $34.00M
Interest Expense $739.00M $783.00M $778.00M $790.00M $688.00M $695.00M $508.00M $318.00M $313.00M $311.00M $293.00M $322.00M $315.00M $325.00M $316.00M $336.00M $347.00M $416.00M $372.00M $390.00M
Depreciation and Amortization $-2.46B $1.75B $1.73B $1.74B $1.67B $1.56B $1.57B $1.49B $1.52B $1.18B $1.18B $1.19B $1.28B $1.36B $1.68B $1.21B $1.05B $1.21B $1.20B $1.17B
EBITDA $729.00M $7.25B $2.40B $5.95B $-1.77B $-1.10B $4.35B $8.07B $7.06B $10.49B $12.91B $10.56B $5.42B $9.52B $8.61B $6.29B $-1.20B $4.47B $4.59B $4.40B
EBITDA Ratio 4.10% 40.97% 27.18% 42.31% 0.54% -12.89% 28.67% 43.04% 31.13% 49.69% 50.90% 44.90% 23.36% 38.85% 38.70% 43.17% 20.57% 36.85% 40.49% 44.68%
Operating Income $3.19B $5.28B $1.88B $4.56B $-1.59B $-3.27B $2.08B $6.38B $6.43B $10.43B $12.95B $10.69B $4.04B $6.47B $5.31B $4.70B $-2.19B $3.33B $3.45B $4.17B
Operating Income Ratio 17.94% 29.85% 14.15% 30.64% -11.18% -24.68% 16.32% 34.91% 26.48% 46.06% 46.67% 41.64% 16.96% 26.87% 27.97% 32.25% -18.74% 27.43% 29.26% 34.65%
Total Other Income Expenses Net $-3.20B $-569.00M $-1.98B $-1.14B $-2.54B $-404.00M $-520.00M $-303.00M $-20.00M $-665.00M $-962.00M $-898.00M $-1.79B $-991.00M $785.00M $521.00M $4.11B $647.00M $500.00M $475.00M
Income Before Tax $-10.00M $4.71B $-103.00M $3.42B $-4.13B $-3.35B $2.27B $6.27B $5.23B $9.00B $11.45B $9.05B $3.83B $7.84B $6.61B $5.68B $178.00M $2.18B $3.95B $3.88B
Income Before Tax Ratio -0.06% 26.64% -0.78% 22.99% -28.98% -25.33% 17.82% 34.30% 21.54% 39.76% 41.26% 35.27% 16.05% 32.52% 34.83% 38.97% 1.52% 17.94% 33.50% 32.30%
Income Tax Expense $-421.00M $234.00M $-134.00M $293.00M $-794.00M $-964.00M $-71.00M $715.00M $230.00M $356.00M $1.57B $1.17B $249.00M $-331.00M $1.04B $805.00M $-170.00M $-26.00M $519.00M $475.00M
Net Income $410.00M $4.46B $24.00M $3.12B $-3.34B $-2.39B $2.33B $5.54B $4.99B $8.61B $9.91B $7.86B $3.39B $8.15B $5.56B $4.88B $594.00M $2.19B $3.49B $3.35B
Net Income Ratio 2.31% 25.22% 0.18% 20.94% -23.47% -18.09% 18.27% 30.32% 20.56% 38.02% 35.71% 30.65% 14.23% 33.81% 29.31% 33.45% 5.08% 18.09% 29.57% 27.89%
EPS $0.07 $0.79 $0.00 $0.55 $-0.59 $-0.42 $0.41 $0.98 $0.89 $1.54 $1.77 $1.40 $0.60 $1.45 $0.99 $0.87 $0.11 $0.39 $0.63 $0.60
EPS Diluted $0.07 $0.78 $0.00 $0.55 $-0.59 $-0.42 $0.41 $0.97 $0.87 $1.51 $1.73 $1.37 $0.59 $1.42 $0.98 $0.86 $0.10 $0.39 $0.62 $0.60
Weighted Average Shares Outstanding 5.67B 5.67B 5.67B 5.66B 5.65B 5.65B 5.65B 5.63B 5.62B 5.61B 5.59B 5.62B 5.62B 5.61B 5.60B 5.58B 5.56B 5.56B 5.55B 5.54B
Weighted Average Shares Outstanding Diluted 5.70B 5.71B 5.70B 5.70B 5.65B 5.65B 5.71B 5.73B 5.74B 5.72B 5.71B 5.76B 5.77B 5.72B 5.68B 5.66B 5.66B 5.63B 5.62B 5.61B
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $- $2.85B $416.00M $1.94B $1.78B
Short Term Investments $- $9.84B $22.32B $29.12B $10.44B
Cash and Short Term Investments $9.95B $12.69B $22.73B $31.07B $12.22B
Net Receivables $- $11.18B $10.95B $11.48B $7.91B
Inventory $- $10.19B $8.98B $9.06B $8.05B
Other Current Assets $- $9.28B $8.59B $8.09B $6.91B
Total Current Assets $9.95B $43.33B $51.26B $59.69B $35.07B
Property Plant Equipment Net $- $21.86B $16.27B $14.88B $13.90B
Goodwill $- $67.78B $51.38B $49.21B $49.58B
Intangible Assets $- $64.90B $43.37B $25.15B $28.47B
Goodwill and Intangible Assets $- $132.68B $94.75B $74.35B $78.05B
Long Term Investments $- $15.77B $15.07B $21.53B $20.26B
Tax Assets $- $3.71B $6.69B $3.34B $2.38B
Other Non-Current Assets $-9.95B $9.14B $13.16B $7.68B $4.57B
Total Non-Current Assets $-9.95B $183.17B $145.94B $121.78B $119.16B
Other Assets $- $- $3.00M $2.00M $-1.00M
Total Assets $- $226.50B $197.21B $181.48B $154.23B
Account Payables $- $6.71B $6.81B $5.58B $4.28B
Short Term Debt $- $10.35B $-462.00M $2.24B $2.70B
Tax Payables $- $2.35B $1.59B $1.27B $1.05B
Deferred Revenue $- $2.70B $2.52B $3.07B $6.27B
Other Current Liabilities $- $25.69B $28.28B $30.52B $16.77B
Total Current Liabilities $- $47.79B $42.14B $42.67B $25.92B
Long Term Debt $- $61.54B $31.93B $34.76B $37.13B
Deferred Revenue Non-Current $- $- $- $16.49B $18.53B
Deferred Tax Liabilities Non-Current $- $640.00M $1.02B $349.00M $4.06B
Other Non-Current Liabilities $-92.56B $27.24B $26.20B $26.24B $23.64B
Total Non-Current Liabilities $-92.56B $89.42B $59.15B $61.34B $64.84B
Other Liabilities $- $- $- $- $-
Total Liabilities $-92.56B $137.21B $101.29B $104.01B $90.76B
Preferred Stock $- $- $- $- $-
Common Stock $- $478.00M $476.00M $473.00M $470.00M
Retained Earnings $- $118.35B $125.66B $103.39B $96.77B
Accumulated Other Comprehensive Income Loss $92.29B $-7.96B $-8.30B $-5.90B $-11.69B
Other Total Stockholders Equity $272.00M $-21.86B $-22.17B $-20.77B $-22.31B
Total Stockholders Equity $92.56B $89.01B $95.66B $77.20B $63.24B
Total Equity $92.56B $89.29B $95.92B $77.46B $63.47B
Total Liabilities and Stockholders Equity $- $226.50B $197.21B $181.48B $154.23B
Minority Interest $- $274.00M $256.00M $262.00M $235.00M
Total Liabilities and Total Equity $- $226.50B $197.21B $181.48B $154.23B
Total Investments $- $25.20B $37.38B $50.65B $30.70B
Total Debt $- $70.84B $34.87B $37.00B $38.27B
Net Debt $- $67.99B $34.45B $35.05B $36.49B


Balance Sheet Charts

Breakdown December 31, 2024 September 29, 2024 June 30, 2024 March 31, 2024 December 31, 2023 October 01, 2023 July 02, 2023 April 02, 2023 December 31, 2022 October 02, 2022 July 03, 2022 April 03, 2022 December 31, 2021 October 03, 2021 July 04, 2021 April 04, 2021 December 31, 2020 September 27, 2020 June 28, 2020 March 29, 2020
Cash and Cash Equivalents $- $1.09B $1.05B $719.00M $2.85B $3.15B $2.63B $2.17B $416.00M $1.30B $1.78B $2.47B $1.94B $1.97B $2.37B $1.77B $1.78B $1.59B $1.80B $2.15B
Short Term Investments $- $8.86B $6.05B $11.21B $9.84B $41.03B $42.15B $17.81B $22.32B $34.83B $31.52B $21.43B $29.12B $27.73B $19.33B $11.90B $10.44B $8.91B $9.58B $8.20B
Cash and Short Term Investments $9.95B $9.95B $7.10B $11.93B $12.69B $44.18B $44.78B $19.97B $22.73B $36.12B $33.30B $23.90B $31.07B $29.70B $21.70B $13.67B $12.22B $10.50B $11.38B $10.35B
Net Receivables $- $14.45B $11.39B $10.99B $11.18B $11.09B $10.23B $12.30B $10.95B $16.08B $15.15B $13.22B $11.48B $11.90B $10.59B $9.86B $7.93B $10.01B $9.13B $9.88B
Inventory $- $11.72B $11.45B $10.89B $10.19B $10.20B $10.31B $9.54B $8.98B $9.51B $10.45B $9.98B $9.06B $8.64B $8.95B $8.49B $8.05B $9.29B $8.56B $8.42B
Other Current Assets $- $7.10B $7.88B $8.61B $9.28B $8.54B $8.02B $8.26B $8.59B $8.69B $8.55B $7.32B $8.09B $7.67B $7.58B $7.51B $6.87B $17.93B $17.35B $6.08B
Total Current Assets $9.95B $43.22B $37.83B $42.41B $43.33B $74.01B $73.35B $50.08B $51.26B $70.40B $67.47B $54.42B $59.69B $57.90B $48.81B $39.53B $35.07B $47.74B $46.42B $34.74B
Property Plant Equipment Net $- $18.54B $18.96B $18.80B $21.86B $17.86B $17.49B $17.05B $16.27B $15.44B $15.24B $15.11B $14.88B $14.44B $14.22B $14.01B $13.90B $14.40B $14.11B $14.04B
Goodwill $- $68.57B $68.44B $69.30B $67.78B $51.53B $51.57B $51.48B $51.38B $49.44B $49.89B $50.21B $49.21B $49.49B $49.87B $49.79B $49.58B $59.90B $58.45B $58.50B
Intangible Assets $- $59.99B $61.24B $62.83B $64.90B $40.22B $41.41B $42.00B $43.37B $28.15B $29.07B $29.82B $25.15B $26.31B $27.32B $27.97B $28.47B $30.93B $33.54B $34.46B
Goodwill and Intangible Assets $- $128.56B $129.69B $132.12B $132.68B $91.75B $92.98B $93.48B $94.75B $77.59B $78.96B $80.03B $74.35B $75.80B $77.19B $77.76B $78.05B $90.83B $91.99B $92.97B
Long Term Investments $- $10.76B $11.52B $12.00B $15.77B $14.65B $15.36B $15.04B $15.07B $13.89B $19.52B $20.74B $21.53B $21.60B $20.94B $20.23B $20.26B $19.01B $18.72B $18.22B
Tax Assets $- $7.91B $7.87B $4.94B $3.71B $8.35B $8.26B $7.30B $6.69B $7.14B $7.00B $5.67B $3.34B $2.75B $2.69B $2.54B $2.38B $2.65B $2.36B $2.21B
Other Non-Current Assets $-9.95B $10.48B $10.34B $10.81B $9.14B $8.39B $12.73B $12.67B $13.16B $10.89B $7.10B $7.88B $7.68B $6.71B $6.06B $4.74B $4.57B $4.36B $4.33B $4.17B
Total Non-Current Assets $-9.95B $176.25B $178.37B $178.68B $183.17B $141.01B $146.82B $145.54B $145.94B $124.95B $127.82B $129.42B $121.78B $121.29B $121.11B $119.28B $119.16B $131.25B $131.51B $131.60B
Other Assets $- $- $- $- $- $- $- $- $3.00M $- $- $1.00M $2.00M $- $- $1.00M $-1.00M $-1.00M $-1.00M $-1.00M
Total Assets $- $219.48B $216.19B $221.09B $226.50B $215.02B $220.17B $195.62B $197.21B $195.35B $195.29B $183.84B $181.48B $179.19B $169.92B $158.82B $154.23B $178.98B $177.93B $166.34B
Account Payables $- $5.31B $5.11B $5.59B $6.71B $5.34B $6.08B $6.12B $6.81B $6.27B $6.21B $5.51B $5.58B $4.70B $4.33B $4.06B $4.31B $4.14B $3.87B $3.97B
Short Term Debt $- $9.70B $9.38B $8.23B $7.57B $2.55B $2.01B $4.19B $-462.00M $4.04B $5.99B $645.00M $2.24B $1.06B $1.87B $4.35B $2.70B $13.36B $13.08B $16.01B
Tax Payables $- $2.88B $2.88B $3.19B $2.35B $1.90B $2.93B $1.97B $1.59B $3.07B $3.35B $3.18B $1.27B $4.50B $1.74B $1.40B $1.05B $1.43B $1.45B $1.15B
Deferred Revenue $- $2.02B $2.53B $2.50B $2.70B $2.20B $1.29B $1.75B $2.52B $6.19B $3.80B $3.11B $3.07B $3.53B $4.29B $2.05B $6.27B $5.97B $5.60B $3.40B
Other Current Liabilities $- $23.30B $21.36B $20.98B $25.68B $19.15B $20.37B $22.53B $28.28B $24.75B $28.06B $26.83B $30.52B $25.45B $21.42B $14.78B $17.86B $15.22B $14.32B $12.76B
Total Current Liabilities $- $43.21B $43.82B $40.50B $47.79B $31.14B $34.65B $36.56B $42.14B $44.31B $47.41B $39.27B $42.67B $41.80B $35.66B $26.65B $25.92B $34.15B $32.72B $33.89B
Long Term Debt $- $58.00B $57.51B $61.31B $61.54B $61.05B $61.36B $31.70B $31.93B $31.65B $34.29B $34.42B $34.76B $36.25B $35.35B $35.35B $37.13B $49.78B $50.53B $36.28B
Deferred Revenue Non-Current $- $- $- $- $2.63B $- $- $- $- $- $- $- $16.49B $17.11B $17.70B $18.43B $18.53B $19.78B $17.90B $18.75B
Deferred Tax Liabilities Non-Current $- $2.16B $2.23B $931.00M $640.00M $1.12B $1.23B $1.07B $1.02B $616.00M $558.00M $655.00M $349.00M $328.00M $4.16B $4.36B $4.06B $4.54B $5.41B $5.27B
Other Non-Current Liabilities $-92.56B $23.55B $24.67B $25.80B $27.24B $24.51B $23.64B $25.05B $26.20B $25.88B $25.56B $26.82B $26.24B $24.84B $24.43B $23.60B $23.64B $25.01B $24.71B $25.56B
Total Non-Current Liabilities $-92.56B $83.71B $84.40B $88.04B $89.42B $86.68B $86.23B $57.82B $59.15B $58.15B $60.41B $61.89B $61.34B $61.42B $63.94B $63.30B $64.84B $79.33B $80.65B $67.11B
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $-92.56B $126.92B $128.22B $128.54B $137.21B $117.82B $120.87B $94.38B $101.29B $102.46B $107.82B $101.16B $104.01B $103.22B $99.61B $89.95B $90.76B $113.49B $113.37B $101.00B
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $17.00M
Common Stock $- $480.00M $480.00M $480.00M $478.00M $478.00M $478.00M $478.00M $476.00M $476.00M $476.00M $476.00M $473.00M $473.00M $472.00M $472.00M $470.00M $470.00M $470.00M $470.00M
Retained Earnings $- $121.06B $116.60B $121.32B $118.35B $126.41B $128.80B $131.10B $125.66B $122.97B $116.61B $111.19B $103.39B $102.25B $96.35B $95.16B $96.77B $100.28B $100.20B $101.00B
Accumulated Other Comprehensive Income Loss $92.29B $-7.97B $-7.82B $-7.76B $-7.96B $-7.97B $-8.10B $-8.29B $-8.30B $-8.22B $-7.12B $-6.16B $-5.90B $-5.65B $-4.76B $-4.66B $-11.69B $-12.68B $-13.25B $-13.13B
Other Total Stockholders Equity $272.00M $-21.28B $-21.56B $-21.76B $-21.86B $-21.99B $-22.15B $-22.32B $-22.17B $-22.59B $-22.76B $-23.09B $-20.77B $-21.39B $-22.02B $-22.35B $-22.31B $-22.82B $-23.09B $-23.33B
Total Stockholders Equity $92.56B $92.29B $87.70B $92.28B $89.01B $96.93B $99.02B $100.97B $95.66B $92.63B $87.21B $82.42B $77.20B $75.69B $70.04B $68.62B $63.24B $65.26B $64.34B $65.03B
Total Equity $92.56B $92.56B $87.97B $92.56B $89.29B $97.20B $99.29B $101.24B $95.92B $92.89B $87.47B $82.69B $77.46B $75.97B $70.31B $68.86B $63.47B $65.50B $64.56B $65.34B
Total Liabilities and Stockholders Equity $- $219.48B $216.19B $221.09B $226.50B $215.02B $220.17B $195.62B $197.21B $195.35B $195.29B $183.84B $181.48B $179.19B $169.92B $158.82B $154.23B $178.98B $177.93B $166.34B
Minority Interest $- $272.00M $275.00M $276.00M $274.00M $270.00M $274.00M $266.00M $256.00M $259.00M $261.00M $261.00M $262.00M $275.00M $273.00M $245.00M $235.00M $236.00M $228.00M $312.00M
Total Liabilities and Total Equity $- $219.48B $216.19B $221.09B $226.50B $215.02B $220.17B $195.62B $197.21B $195.35B $195.29B $183.84B $181.48B $179.19B $169.92B $158.82B $154.23B $178.98B $177.93B $166.34B
Total Investments $- $19.62B $17.57B $23.21B $25.61B $55.69B $57.51B $32.84B $37.38B $48.71B $51.05B $42.16B $50.65B $49.33B $40.27B $32.13B $30.70B $27.92B $28.30B $26.42B
Total Debt $- $66.62B $69.45B $69.54B $75.04B $63.60B $65.34B $35.89B $34.87B $35.68B $40.28B $35.05B $37.00B $38.41B $37.73B $38.19B $38.27B $61.53B $63.61B $52.28B
Net Debt $- $65.53B $68.40B $68.82B $72.19B $60.45B $62.71B $33.73B $34.45B $34.38B $38.50B $32.58B $35.05B $36.44B $35.36B $36.42B $36.49B $59.94B $61.81B $50.13B

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $8.03B $2.17B $31.40B $22.46B $7.02B
Depreciation and Amortization $- $6.29B $5.06B $5.19B $4.78B
Deferred Income Tax $- $-3.44B $-3.76B $-4.29B $-1.47B
Stock Based Compensation $- $525.00M $872.00M $1.18B $756.00M
Change in Working Capital $- $-2.17B $-4.46B $12.80B $-275.00M
Accounts Receivables $- $347.00M $261.00M $-3.81B $-1.25B
Inventory $- $6.20B $592.00M $-1.12B $-736.00M
Accounts Payables $- $-300.00M $1.19B $1.24B $353.00M
Other Working Capital $- $-8.42B $-6.50B $16.50B $1.36B
Other Non Cash Items $-8.03B $5.33B $150.00M $-4.76B $3.59B
Net Cash Provided by Operating Activities $- $8.70B $29.27B $32.58B $14.40B
Investments in Property Plant and Equipment $- $-3.91B $-3.24B $-2.71B $-2.79B
Acquisitions Net $- $-43.43B $-23.00B $-12.00M $-621.00M
Purchases of Investments $- $-31.18B $-38.78B $-47.61B $-14.40B
Sales Maturities of Investments $- $46.42B $45.46B $28.10B $12.73B
Other Investing Activities $- $-180.00M $3.77B $-306.00M $813.00M
Net Cash Used for Investing Activities $- $-32.28B $-15.78B $-22.55B $-4.27B
Debt Repayment $- $35.95B $-3.52B $-1.10B $-12.76B
Common Stock Issued $- $- $- $- $-
Common Stock Repurchased $- $- $-2.00B $- $-
Dividends Paid $- $-9.25B $-8.98B $-8.73B $-8.44B
Other Financing Activities $- $-632.00M $-335.00M $16.00M $11.55B
Net Cash Used Provided by Financing Activities $- $26.07B $-14.83B $-9.82B $-9.65B
Effect of Forex Changes on Cash $- $-40.00M $-165.00M $-59.00M $-8.00M
Net Change in Cash $-2.92B $2.45B $-1.51B $158.00M $475.00M
Cash at End of Period $- $2.92B $468.00M $1.98B $1.82B
Cash at Beginning of Period $2.92B $468.00M $1.98B $1.82B $1.35B
Operating Cash Flow $- $8.70B $29.27B $32.58B $14.40B
Capital Expenditure $- $-3.91B $-3.24B $-2.71B $-2.79B
Free Cash Flow $- $4.79B $26.03B $29.87B $11.61B

Cash Flow Charts

Breakdown December 31, 2024 September 29, 2024 June 30, 2024 March 31, 2024 December 31, 2023 October 01, 2023 July 02, 2023 April 02, 2023 December 31, 2022 October 02, 2022 July 03, 2022 April 03, 2022 December 31, 2021 October 03, 2021 July 04, 2021 April 04, 2021 December 31, 2020 September 27, 2020 June 28, 2020 March 29, 2020
Net Income $410.00M $4.47B $24.00M $3.12B $-3.34B $-2.39B $2.33B $5.54B $5.00B $8.64B $9.87B $7.88B $3.85B $8.17B $5.57B $4.88B $-2.02B $2.20B $3.44B $3.41B
Depreciation and Amortization $- $1.75B $1.73B $1.74B $1.67B $1.56B $1.57B $1.49B $1.52B $1.18B $1.18B $1.19B $1.28B $1.36B $1.33B $1.23B $1.05B $1.26B $1.25B $1.22B
Deferred Income Tax $- $-482.00M $-783.00M $-441.00M $-1.86B $-113.00M $-873.00M $-598.00M $-365.00M $62.00M $-1.14B $-2.32B $-591.00M $-3.75B $-152.00M $199.00M $-871.00M $-668.00M $-38.00M $109.00M
Stock Based Compensation $- $274.00M $206.00M $220.00M $121.00M $151.00M $148.00M $105.00M $364.00M $135.00M $287.00M $86.00M $495.00M $293.00M $221.00M $172.00M $264.00M $224.00M $187.00M $57.00M
Change in Working Capital $- $6.87B $-3.54B $-3.34B $8.45B $-1.20B $-3.92B $-5.51B $3.15B $-4.11B $-2.77B $-730.00M $1.99B $6.42B $5.72B $-1.33B $2.81B $-851.00M $-648.00M $-1.58B
Accounts Receivables $- $- $- $- $347.00M $- $- $- $261.00M $- $- $- $-3.81B $- $- $- $-1.25B $- $- $-
Inventory $- $- $- $- $-1.17B $- $- $- $592.00M $- $- $- $-1.12B $- $- $- $-736.00M $- $- $-
Accounts Payables $- $- $- $- $822.00M $- $- $- $1.19B $- $- $- $1.24B $- $- $- $353.00M $- $- $-
Other Working Capital $- $6.87B $-3.54B $-3.34B $8.45B $-1.20B $-3.92B $-5.51B $1.10B $-4.11B $-2.77B $-730.00M $5.68B $6.76B $5.38B $-1.33B $4.44B $-851.00M $-648.00M $-1.58B
Other Non Cash Items $-410.00M $-6.18B $4.24B $3.48B $201.00M $5.45B $-470.00M $184.00M $-1.09B $59.00M $3.38B $440.00M $-1.10B $-1.66B $-1.39B $-609.00M $4.41B $-88.00M $-639.00M $-87.00M
Net Cash Provided by Operating Activities $- $6.71B $-1.78B $1.09B $5.24B $3.46B $-1.21B $1.21B $8.58B $5.97B $8.17B $6.54B $5.91B $10.83B $11.30B $4.54B $5.62B $2.09B $3.56B $3.13B
Investments in Property Plant and Equipment $- $-651.00M $-637.00M $-704.00M $-1.04B $-810.00M $-914.00M $-1.14B $-1.00B $-841.00M $-751.00M $-643.00M $-993.00M $-624.00M $-540.00M $-554.00M $-1.29B $-530.00M $-480.00M $-495.00M
Acquisitions Net $- $- $- $3.49B $-43.41B $-2.00M $-25.00M $-1.00M $-16.77B $- $- $-6.22B $-12.00M $- $- $- $-583.00M $-5.00M $-1.00M $-32.00M
Purchases of Investments $- $-2.67B $657.00M $-2.02B $-874.00M $-9.21B $-14.38B $-6.72B $3.42B $-18.79B $-17.39B $-9.43B $-13.32B $-17.71B $-9.51B $-7.08B $5.93B $-3.08B $-14.27B $-2.99B
Sales Maturities of Investments $- $1.26B $4.60B $4.45B $34.31B $10.56B $-9.64B $11.19B $9.93B $15.16B $6.90B $16.88B $11.68B $8.55B $2.15B $5.72B $3.69B $3.91B $1.72B $3.41B
Other Investing Activities $- $6.00M $-18.00M $1.00M $15.00M $350.00M $-524.00M $-18.00M $9.00M $3.85B $-77.00M $-13.00M $64.00M $-298.00M $-235.00M $163.00M $582.00M $178.00M $17.00M $36.00M
Net Cash Used for Investing Activities $- $-2.06B $4.60B $1.73B $-11.00B $888.00M $-25.48B $3.31B $-4.41B $-627.00M $-11.31B $567.00M $-2.59B $-10.08B $-8.14B $-1.75B $8.33B $481.00M $-13.01B $-71.00M
Debt Repayment $- $-2.25B $-16.00M $-2.17B $7.78B $-1.43B $29.63B $-32.00M $-2.78B $-3.52B $4.61B $-1.83B $-1.36B $759.00M $-474.00M $-25.00M $-23.48B $-647.00M $11.32B $18.00M
Common Stock Issued $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $425.00M $- $- $-
Common Stock Repurchased $- $- $- $- $- $- $- $- $2.00K $- $- $-2.00B $- $- $- $- $-1.32B $- $- $-
Dividends Paid $- $-2.38B $-2.38B $-2.37B $-2.31B $-2.31B $-2.31B $-2.30B $-2.25B $-2.25B $-2.24B $-2.25B $-2.19B $-2.19B $-2.18B $-2.17B $-2.11B $-2.11B $-2.11B $-2.10B
Other Financing Activities $- $-6.00M $-63.00M $-386.00M $-18.00M $-37.00M $-141.00M $-436.00M $7.00M $5.00M $153.00M $-500.00M $201.00M $325.00M $100.00M $-610.00M $11.80B $-62.00M $-50.00M $-113.00M
Net Cash Used Provided by Financing Activities $- $-4.64B $-2.46B $-4.93B $5.44B $-3.78B $27.17B $-2.77B $-5.01B $-5.76B $2.52B $-6.58B $-3.35B $-1.10B $-2.56B $-2.81B $-13.79B $-2.82B $9.16B $-2.20B
Effect of Forex Changes on Cash $- $9.00M $-18.00M $-28.00M $-1.00M $-32.00M $-5.00M $-2.00M $-26.00M $-72.00M $-66.00M $-1.00M $-27.00M $-37.00M $5.00M $- $31.00M $31.00M $-55.00M $-15.00M
Net Change in Cash $-1.15B $100.00M $333.00M $-2.13B $-295.00M $516.00M $466.00M $1.75B $-870.00M $-486.00M $-690.00M $530.00M $-51.00M $-384.00M $609.00M $-16.00M $198.00M $-218.00M $-351.00M $846.00M
Cash at End of Period $- $1.15B $1.05B $719.00M $2.85B $3.15B $2.63B $2.17B $468.00M $1.34B $1.78B $2.51B $1.98B $2.03B $2.42B $1.81B $1.82B $1.63B $1.84B $2.20B
Cash at Beginning of Period $1.15B $1.05B $719.00M $2.85B $3.15B $2.63B $2.17B $416.00M $1.34B $1.82B $2.47B $1.98B $2.03B $2.42B $1.81B $1.82B $1.63B $1.84B $2.20B $1.35B
Operating Cash Flow $- $6.71B $-1.78B $1.09B $5.24B $3.46B $-1.21B $1.21B $8.58B $5.97B $8.17B $6.54B $5.91B $10.83B $11.30B $4.54B $5.62B $2.09B $3.56B $3.13B
Capital Expenditure $- $-651.00M $-637.00M $-704.00M $-1.04B $-810.00M $-914.00M $-1.14B $-1.00B $-841.00M $-751.00M $-643.00M $-993.00M $-624.00M $-540.00M $-554.00M $-1.29B $-530.00M $-480.00M $-495.00M
Free Cash Flow $- $6.06B $-2.42B $387.00M $4.20B $2.65B $-2.12B $74.00M $7.58B $5.13B $7.42B $5.90B $4.92B $10.21B $10.76B $3.98B $4.34B $1.56B $3.08B $2.64B


Pfizer Stock Forecast

Analyst ratings, price targets, and earnings estimates for PFE.

PFE Analyst Ratings

Hold

Buy
9
Hold
11
Sell
1

Based on 21 analysts in the past 3 months

PFE Stock 12 Month Forecast

$32.00

▲ (25.34% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$32.00 (25.3%)
Lowest Price Target
$ (0.0%)

Based on 1 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $63.12B
Average $62.94B
Low $62.68B
15 analysts
Net Income Estimates
High $17.11B
Average $16.74B
Low $16.37B
15 analysts
EPS Estimates
High $3.00
Average $2.94
Low $2.87
13 analysts
Revenue Estimates
High $64.04B
Average $62.93B
Low $61.48B
16 analysts
Net Income Estimates
High $18.62B
Average $17.07B
Low $15.53B
16 analysts
EPS Estimates
High $3.27
Average $3.05
Low $2.72
13 analysts
Revenue Estimates
High $62.06B
Average $61.89B
Low $61.72B
14 analysts
Net Income Estimates
High $23.07B
Average $18.47B
Low $13.88B
14 analysts
EPS Estimates
High $4.05
Average $3.04
Low $2.43
7 analysts
Revenue Estimates
High $60.61B
Average $59.39B
Low $58.10B
6 analysts
Net Income Estimates
High $16.72B
Average $16.28B
Low $15.82B
6 analysts
EPS Estimates
High $2.93
Average $2.86
Low $2.78
4 analysts
Revenue Estimates
High $58.33B
Average $57.15B
Low $55.91B
8 analysts
Net Income Estimates
High $15.64B
Average $15.23B
Low $14.80B
8 analysts
EPS Estimates
High $2.74
Average $2.67
Low $2.60
2 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Dec 18, 2024 Robyn Karnauskas Truist Financial $32.00 $25.89 23.6%
Oct 30, 2024 Chris Shibutani Goldman Sachs $33.00 $28.46 16.0%
Oct 17, 2024 Courtney Breen Bernstein $32.00 $29.67 7.9%
Sep 25, 2024 Carter Gould Barclays $32.00 $28.93 10.6%
Aug 07, 2024 Narumi Nakagiri Daiwa $34.00 $28.85 17.9%
Jul 31, 2024 Mohit Bansal Wells Fargo $30.00 $31.39 -4.4%
Jul 31, 2024 Chris Shibutani Goldman Sachs $34.00 $31.39 8.3%
Jul 30, 2024 Vamil Divan Guggenheim $36.00 $30.72 17.2%
Jul 10, 2024 Carter Gould Barclays $30.00 $27.72 8.2%
May 22, 2024 Evan Seigerman BMO Capital $36.00 $29.60 21.6%

Pfizer Dividends

Explore Pfizer's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

-

Dividend Payout Ratio

-

Dividend Paid & Capex Coverage Ratio

0.00x



Pfizer Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.43 $0.43 January 24, 2025 January 24, 2025 March 07, 2025 December 12, 2024
$0.42 $0.42 November 08, 2024 November 08, 2024 December 02, 2024 October 09, 2024
$0.42 $0.42 July 26, 2024 July 26, 2024 September 03, 2024 June 26, 2024
$0.42 $0.42 May 09, 2024 May 10, 2024 June 14, 2024 April 24, 2024
$0.42 $0.42 January 25, 2024 January 26, 2024 March 01, 2024 December 14, 2023
$0.41 $0.41 November 09, 2023 November 10, 2023 December 04, 2023 October 04, 2023
$0.41 $0.41 July 27, 2023 July 28, 2023 September 05, 2023 June 22, 2023
$0.41 $0.41 May 11, 2023 May 12, 2023 June 09, 2023 April 26, 2023
$0.41 $0.41 January 26, 2023 January 27, 2023 March 03, 2023 December 09, 2022
$0.4 $0.4 November 03, 2022 November 04, 2022 December 05, 2022 September 22, 2022
$0.4 $0.4 July 28, 2022 July 29, 2022 September 06, 2022 June 23, 2022
$0.4 $0.4 May 12, 2022 May 13, 2022 June 10, 2022 April 28, 2022
$0.4 $0.4 January 27, 2022 January 28, 2022 March 04, 2022 December 10, 2021
$0.39 $0.39 November 04, 2021 November 05, 2021 December 06, 2021 September 23, 2021
$0.39 $0.39 July 29, 2021 July 30, 2021 September 07, 2021 June 24, 2021
$0.39 $0.39 May 06, 2021 May 07, 2021 June 04, 2021 April 22, 2021
$0.39 $0.39 January 28, 2021 January 29, 2021 March 05, 2021 December 11, 2020
$0.38 $0.38 November 05, 2020 November 06, 2020 December 01, 2020 September 24, 2020
$0.38 $0.38 July 30, 2020 July 31, 2020 September 01, 2020 June 25, 2020
$0.38 $0.38 May 07, 2020 May 08, 2020 June 05, 2020 April 23, 2020

Peers: Drug Manufacturers - General

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
ABBV Logo
AbbVie Inc.
ABBV
$340.83B $192.87 $2.75 $56.34 $26.45
MRK Logo
Merck & Co., Inc.
MRK
$209.99B $83.01 $0.14 $778.71 $7.56
LLY Logo
Eli Lilly and Company
LLY
$801.48B $844.27 $11.71 $65.93 $48.75
BMY Logo
Bristol-Myers Squibb Company
BMY
$109.32B $53.90 $-4.41 $-12.82 $7.02
JNJ Logo
Johnson & Johnson
JNJ
$375.95B $156.15 $5.84 $24.53 $27385.90
AMGN Logo
Amgen Inc.
AMGN
$156.51B $291.16 $7.56 $34.48 $23.99
GILD Logo
Gilead Sciences, Inc.
GILD
$129.71B $104.08 $0.38 $239.97 $0.00
Ownership